 | This article needs additional citations for verification. (August 2012) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD30 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6358H9830N1682O1992S38 |
| Molar mass | 142922.64 g·mol−1 |
  (what is this?) (verify) | |
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.[1]
This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.
The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.[2]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab, American Medical Association.
- ^ "Iratumumab". AdisInsight. Retrieved 30 January 2017.